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 Abstract  
Pneumococcal meningitis is the most frequent and critical type of bacterial meningitis. As 
cytokines play an important role in the pathogenesis of bacterial meningitis, we examined 
whether functional polymorphisms of the pro-inflammatory cytokine macrophage migration 
inhibitory factor (MIF) were associated with morbidity and mortality of pneumococcal 
meningitis. Two functional MIF promoter polymorphisms, a microsatellite (-794 CATT5-8; 
rs5844572) and a single nucleotide polymorphism (-173 G/C; rs755622) were genotyped 
in a prospective, nationwide cohort of 405 patients with pneumococcal meningitis and in 
329 controls matched for age, gender and ethnicity. Carriages of the CATT7 and -173 C 
high expression MIF alleles were associated with unfavorable outcome (P=0.005 and 
P=0.003) and death (P=0.03 and P=0.01). In a multivariate logistic regression model, 
shock (OR 26.0, P=0.02) and carriage of the CATT7 allele (OR 5.12, P=0.04) were the 
main predictors of mortality. MIF levels in the cerebrospinal fluid (CSF) were associated 
with systemic complications and death (P=0.0002). Streptococcus pneumoniae strongly 
up-regulated MIF production in whole blood and transcription activity of high expression 
MIF promoter Luciferase reporter constructs in THP-1 monocytes. Consistent with these 
findings, treatment with anti-MIF IgG antibodies reduced bacterial loads and improved 
survival in a mouse model of pneumococcal pneumonia and sepsis. The present study 
provides strong evidence that carriage of high expression MIF alleles is a genetic marker 
of morbidity and mortality of pneumococcal meningitis and also suggests a potential role 
for MIF as a target of immune modulating adjunctive therapy.  
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Significance Statement  
Pneumococcal meningitis, the most frequent cause of bacterial meningitis in adults, is 
associated with substantial morbidity and mortality. In a prospective, nationwide cohort of 
patients with pneumococcal meningitis, macrophage migration inhibitory factor (MIF), a 
proinflammatory mediator, was identified as a novel genetic marker of patient’s outcome. 
High expression MIF alleles were associated with disease severity and death, a finding 
consistent with the harmful consequences of robust proinflammatory cytokine responses 
on brain edema and neuronal damage in the course of bacterial meningitis. These results 
provide strong evidence that functional MIF polymorphisms are genetic predictors of 
morbidity and mortality of pneumococcal meningitis and suggest that MIF is potential 
target for immune modulating adjunctive therapies. 
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Introduction 
Acute community-acquired bacterial meningitis is a life-threatening disease 
associated with substantial morbidity and mortality and ranks among the top ten infectious 
causes of death (1). Streptococcus pneumoniae (S. pneumoniae) is the most common 
cause of bacterial meningitis in adults of all-age groups, accounting for 50% to 70% of 
cases in developed countries (2). Pneumococcal meningitis is associated with a mortality 
ranging from 19% to 37% (3, 4). Neurological sequelae such as hearing loss, focal deficits, 
motor and cognitive impairments significantly affect the quality of life of survivors (5-7). 
Predisposing factors for pneumococcal meningitis include pneumonia, otitis, sinusitis, 
cerebrospinal fluid leaks, splenectomy or asplenic states, debilitating conditions (i.e. 
alcoholism, cirrhosis, diabetes and cancer) and primary or acquired immune deficiencies 
(i.e. multiple myeloma, hypogammaglobulinemia, sickle cell anemia, HIV/AIDS and the use 
of immunosuppressive agents). Genetic studies of extreme phenotypes have revealed that 
patients with single-gene inborn errors in MyD88, IRAK4 and NEMO affecting the 
activation of the canonical TLR and IL-1R signaling pathways or in complement factor two 
are prone to pneumococcal diseases (8, 9). In addition, case-control candidate gene 
studies identified polymorphisms of genes associated either with increased susceptibility 
(MBL2, PTPN22) to or with protection (TIRAP, NFKBIA, NFKBIE) from pneumococcal 
disease (2, 8, 9). The increased susceptibility was related to reduced concentrations of the 
mannose binding lectin (variants of MBL2) or to an increased activity of the PTPN22 
phosphatase (variants of PTPN22) (10, 11). The protection afforded by the polymorphic 
TIRAP variant is mediated by an attenuation of TLR2 signal transduction due to a 
defective recruitment of the TIRAP variant to TLR2 (12). The functional effects of the 
polymorphisms of the NFKBIA and NFKBIE genes coding for the inhibitors of NF-κB (IκB) 
are unknown (13). 
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Cytokines are critical effector molecules of the immune system and play a central 
role in the orchestration of host defenses against infection. Up until now no polymorphism 
of cytokine genes (including TNF, IL6, IL10 and LTA) has been associated with 
susceptibility to and outcome of invasive pneumococcal infection (2). Within this large 
family of mediators, macrophage migration inhibitory factor (MIF) occupies a special place 
(14, 15). Unrelated to classical cytokine families (tumor necrosis factor, chemokines, 
interleukins or interferons), MIF is a constitutively expressed pro-inflammatory cytokine 
acting at the interface of the immune and endocrine systems. Within the innate immune 
system, MIF positively regulates TLR4 expression, inhibits activation-induced and p53-
dependent apoptosis of macrophages and counter-regulates the anti-inflammatory and 
immunosuppressive effects of glucocorticoids in part by a down-regulation of mitogen-
activated protein kinase phosphatase-1 (MKP-1) (16-19). MIF is up-regulated in 
inflammatory, infectious and auto-immune diseases functioning as a modulator of innate 
and adaptive immunity (20-22). 
 Functional polymorphisms of the MIF gene locus include a microsatellite repeat of 
five to eight CATT tetranucleotide (CATT5-8) at position -794 (rs5844572) and a single 
nucleotide polymorphism (SNP) of a G to C transition at position -173 (-173G/C) 
(rs755622) (23, 24). Genetic studies have revealed a complex picture of the role of 
polymorphic MIF alleles in the pathogenesis of auto-immune diseases (20, 25). Few 
studies have been performed in patients with infectious diseases, especially in patients 
with bacterial sepsis (20, 25). We therefore examined the impact of the MIF gene locus on 
the susceptibility to, severity and outcome of pneumococcal meningitis in a large, 
nationwide cohort of patients. Functional studies of polymorphic MIF promoters were 
conducted in human monocytic cells stimulated with S. pneumoniae and analyzed by 
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Luciferase reporter assays. Lastly, the effect of an anti-MIF treatment strategy was 
evaluated in a mouse model of S. pneumoniae pneumonia and sepsis.  
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Results 
Pneumococcal meningitis cohort. A total of 461 patients with culture-proven, 
community-acquired S. pneumoniae meningitis and 343 controls matched for age (median, 
59.4 years vs. 60.1 years), gender (female: 53% vs. 50.8%) and ethnicity (Caucasian: 94.2 
vs. 96.0%) were enrolled in a prospective, nationwide cohort study. DNA samples were 
available from 434 patients and 329 controls who were all Caucasians. The baseline 
characteristics of patients are shown in Table 1. Briefly, 80.4% of the patients were 
bacteremic and 43.7% required ICU admission for shock or respiratory failure. During 
hospitalization, 79.6% developed neurological complications and 38.1% systemic 
complications. Outcome was unfavorable (defined as a Glasgow Outcome Score of 1 to 4) 
in 133 patients (32.8%). Thirty patients (7.5%) died (Glasgow Outcome Score of 1).  
Association between MIF polymorphisms and susceptibility to, severity and 
outcome of pneumococcal meningitis. Allelic frequencies and genotypes for the -173 
G/C (rs755622) and CATT5-8 (rs5844572) polymorphisms of patients and controls are 
presented in Supplementary Table 1. No deviation from the Hardy-Weinberg equilibrium 
was observed for the -173 G/C SNP and CATT5-8 microsatellite. The allele frequencies, 
genotypes and haplotypes of the -173 G/C and of the CATT5-8 polymorphisms were similar 
in patients and controls (P>0.5) indicating that there was no association between MIF 
polymorphisms and susceptibility to pneumococcal meningitis. Carriage of the -173 C or of 
the CATT7 high MIF expression alleles were associated with unfavorable outcome (-173 C: 
OR 1.9, P=0.003; CATT7: OR 1.89, P=0.005), respiratory failure (-173 C: OR 1.71, P=0.03) 
and death (-173 C: OR: 2.6, P=0.01; CATT7: OR 2.27, P=0.03) (Table 2). The association 
between the -173 C or CATT7 high MIF expression allelic variants and death was also 
significant using an additive mode of inheritance (Figure 1). Carriage of the CATT7 allele 
was associated with markers of inflammation such as C-reactive protein (P=0.02) and 
7 
 
erythrocyte sedimentation rate (P=0.02) and with indicator of disease’s severity (i.e. a CSF 
leukocyte count below 1000 cells per mm3) (P=0.05) (22). The association between the 
CATT7 and death remained significant in a multivariate logistic regression model (OR 5.12, 
P=0.04) and tended to be associated with unfavorable outcome (OR 2.61, P=0.07) after 
adjustment for relevant co-variables (Table 3). 
MIF levels in the CSF and morbidity and mortality of pneumococcal 
meningitis. MIF CSF levels were measured in 242 patients (52% of the patients included 
in the study). The median concentration was 2.65 ng/ml (range: 0.025 to 323 ng/ml). The 
MIF CSF levels were similar in patients in whom antibiotic treatment was started before or 
after the lumbar puncture (median [range]: 2.49 [0.02-323.22] versus 3.49 [0.02-68.34] 
ng/ml, P=0.22). MIF CSF levels were markedly higher in non-survivors than in survivors 
(10.80 [3.29-89.11] versus 3.19 [0.02-323.22] ng/ml, P=0.0002) and also higher in patients 
with than in patients without unfavorable outcome (P=0.0001), respiratory failure (P=0.006) 
or systemic complications (P=0.0004) (Supplementary Figure 1). 
S. pneumoniae induces MIF production in whole blood and MIF promoter 
activity in THP-1 monocytes. Given that MIF polymorphisms and MIF levels in the CSF 
were associated with morbidity and mortality of pneumococcal meningitis, we examined 
whether S. pneumoniae up-regulated blood levels of MIF and whether polymorphic MIF 
alleles affected the transcriptional activity of the MIF promoter. S. pneumoniae induced a 
strong and dose-dependent up-regulation of MIF production in human whole blood (Figure 
2A). After 24 hours, the median concentrations of MIF in cell culture supernatants 
increased 2.4-fold, 3.8-fold and 15.5-fold upon stimulation with 2 x 106, 2 x 107 and 2 x 108 
CFU/ml of S. pneumoniae (P=0.005, P=0.001 and P<10-8 when compared with 
unstimulated control cells). We then evaluated the transcriptional activity of the four most 
common polymorphic MIF promoters (CATT5/-173 G, CATT6/-173 G, CATT6/-173 C and 
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CATT7/-173 C) in human THP-1 monocytes (Figure 2B). The transcriptional activity was 
up-regulated after stimulation with S. pneumoniae and was highest with the CATT6/-173 C 
and CATT7/-173 C constructs (P=0.03 and P=0.003 when compared with CATT5/-173 G). 
Anti-MIF antibody protects against lethal pneumococcal pneumonia and 
sepsis. Given that high-expression MIF alleles and high MIF CSF levels were associated 
with poor patient’s outcome, we tested the impact of anti-MIF treatment strategy in a 
mouse model of pneumococcal pneumonia and sepsis (Figure 3). When compared with 
mice treated with control antibody, mice treated with anti-MIF antibody had lower bacterial 
counts in the lung (median [range] log CFU per gram of tissue: 3.8 [1 – 9.2] versus 1 [1 -
7.9], P=0.008) and higher survival (25% versus 53.6%, P=0.04) indicating that 
neutralization of MIF was associated with enhanced bacterial clearance and substantial 
survival benefit in this lethal model of pneumococcal sepsis. 
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Discussion 
In this large, nationwide and well characterized cohort of patients with community-
acquired pneumococcal meningitis, high-expression MIF alleles and elevated levels of MIF 
in the CSF were identified as predictors of morbidity and mortality. These results suggest 
that a vigorous MIF response is detrimental in patients with pneumococcal meningitis, a 
finding consistent with the harmful consequences of robust proinflammatory cytokine 
responses on brain edema and neuronal damage in the course of bacterial meningitis (26).  
Up to now studies of polymorphisms of cytokine genes have failed to demonstrate 
association between TNF, IL6, IL10 or LTA and the susceptibility to or the outcome of 
bacterial meningitis (2). MIF is therefore the first cytokine whose gene polymorphisms are 
associated with morbidity and mortality of bacterial meningitis. MIF may exert its effects by 
promoting the migration, tissue seeding and survival of myeloid cells (such as neutrophils 
and monocytes) that are important players in the pathogenesis of bacterial meningitis (26, 
27). At a cellular level, MIF up-regulates pro-inflammatory responses of immune cells via 
the activation the MAPK and PI3K/Akt signaling pathways downstream of the CD74-CD44 
and CXCR2-CXCR4 MIF receptor complex, which is likely to be detrimental in patients 
with bacterial meningitis (26, 27). 
Few and fairly small studies looked at MIF in patients with pneumococcal diseases 
(28, 29). Elevated levels of MIF were detected in the CSF of 31 patients with bacterial 
meningitis (29). Albeit higher in 11 patients with pneumococcal meningitis than in 15 
patients with meningococcal meningitis, MIF CSF levels were not associated with patient’s 
outcome. In a study that included 15 patients with pneumococcal meningitis, the frequency 
of the CATT7 allele, but not that of the -173 C allele, was higher in patients with meningitis 
than in those with non-CNS pneumococcal infections (28). Associations between MIF 
genotypes and other clinical variables were not reported. Moreover, given the absence of 
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uninfected control subjects, it was not possible to determine whether the carriage of a 
CATT7 allele was a risk factor for the development of pneumococcal meningitis. The 
present study included a large number of patients and had sufficient power to examine 
these questions. Neither the CATT5-8 nor the -173 G/C MIF polymorphisms was a risk 
factor for susceptibility to pneumococcal meningitis. Yet, high expression MIF alleles and 
high levels of MIF levels in the CSF were associated with markers of inflammation, 
indicators of disease’s severity, complications and mortality.   
Studies exploring the relationship between functional polymorphisms of the MIF gene 
locus and susceptibility to, severity and outcome of infectious and auto-immune diseases 
have yielded a complex global picture (20, 25). In clinical studies of infectious diseases, 
carriage of high-expression MIF alleles (CATT7/8) or haplotypes (CATT6/7/-173 C) was 
associated with severe complications of malaria (30), with mortality in patients with severe 
sepsis (31) and with survival in patients with community-acquired pneumonia (32). 
Carriage of the low-expression MIF allele (CATT5) protected children from 
meningococcemia (33), but it predisposed older adults to Gram-negative bacteremia (34). 
Notwithstanding the possibility that the impact of MIF polymorphisms may vary according 
to the age of the host, the site of infections and the type of microorganism, it also is 
possible that confounding factors (such as selection biases, ambiguous phenotypes, 
patient and pathogen heterogeneity and lack of power) account for these discrepant 
findings (2, 35, 36). To minimize the influence of potential confounders, we elected to 
conduct our study in a large and homogeneous cohort of patients with community-acquired 
bacterial meningitis caused by a single pathogen (S. pneumoniae). One of the strengths of 
the study was the use of a well-defined phenotype. Working with a nationwide cohort also 
protected against the potential risk of single center biases. The choice of controls (patient’s 
partners or proxies) limited the risk of socio-economic and environmental mismatching. 
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Power calculations indicated that the study had 80% power to detect odds ratios in the 
range of 1.5 to 3.0 for the main study endpoints. 
The study has also some limitations. It included only Caucasians. Given that MIF 
polymorphisms are unequally distributed in different populations (20), our findings might 
therefore not be extrapolated to other races or ethnic groups. Blood samples were not 
available to measure MIF in the systemic circulation. Yet, one study looking at MIF levels 
in patients with CNS infections did not find an association between MIF levels in the CSF 
and inflammation biomarkers in the systemic circulation (37-40). Attempts to correlate MIF 
polymorphisms with MIF CSF levels were unsuccessful. This may be due to the relatively 
limited number of CSF and DNA specimen pairs. Additionally, the range of MIF CSF levels 
was rather broad, likely because lumbar punctures were performed in patients at different 
stages of the disease. It is also conceivable that carriage of a high expression MIF allele 
plays a detrimental role at the very early stage of disease, promoting inflammation, blood 
brain barrier disruption and bacterial neuro-invasion, as shown both for MIF or interferon 
lambda in West Nile encephalitis (41, 42). MIF-driven early pathogenic effects may indeed 
not be correlated with CSF parameters measured just once at a later stage of the disease. 
In that scenario, both MIF polymorphisms and MIF expression levels might be independent 
markers of severity at different stages of the disease. Finally, given that MIF is 
constitutively expressed by innate immune cells and markedly up-regulated upon infection, 
the release of intracellular MIF pools from dying cells may have increased MIF levels in the 
CSF compromising pair wise analyses of MIF gene polymorphisms and MIF protein levels. 
 A large body of experimental and clinical evidence indicates that MIF is an upstream 
mediator of the host antimicrobial defense response and a powerful immunomodulating 
cytokine. It has therefore been investigated as a target for therapeutic interventions in 
infectious, inflammatory and autoimmune diseases (19, 32-34, 37-40, 43-45). The 
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observation that MIF is a genetic marker of morbidity and mortality of pneumococcal 
meningitis is in line with the results obtained in animal models of sepsis and in clinical 
studies that have linked high levels of MIF with life-threatening bacterial infections (21, 22, 
46-49). In a murine model of pneumococcal colonization, the clearance of pneumococci 
from the nasopharynx, a critical step in the pathogenesis of invasive pneumococcal 
diseases, was more rapid in wild-type mice than in MIF-deficient mice (45). This finding 
suggested that MIF might be a protective factor against pneumococcal diseases. However, 
in the present study there was no relationship between MIF expression and susceptibility 
to pneumococcal meningitis. In a model of pneumococcal pneumonia, wild-type mice had 
higher bacterial load, higher innate immune cell counts in the lung parenchyma, more 
severe lung pathology and a higher mortality rate than MIF-deficient mice (50), indicating 
that MIF played a detrimental role in severe pneumococcal infection. Consistent with this 
observation, high MIF expression alleles and MIF CSF levels were predictors of disease 
severity and poor outcome in patients with pneumococcal meningitis. Furthermore, anti-
MIF therapy using either neutralizing antibodies (present study) or a small-molecule 
inhibitor of MIF (50) promoted bacterial clearance and increased survival in a lethal 
pneumococcal sepsis. Likewise, humanized anti-MIF antibodies were shown to be 
protective in a lethal mouse E. coli peritonitis model (51). A first-in-class anti-MIF 
monoclonal antibody (BAX69/imalumab) is currently under evaluation in phase 1/2a 
clinical trials in patients with metastatic colorectal cancer or with ovarian cancer and 
malignant ascites.  
 Altogether, the present study provides strong evidence that carriage of high 
expression MIF alleles is a genetic marker of morbidity and mortality of pneumococcal 
meningitis and also suggests a potential role for MIF as a target of immune modulating 
adjunctive therapies for bacterial meningitis and sepsis. 
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Materials and Methods 
Bacteria preparation and whole-blood stimulation assay. A serotype 19 S. 
pneumoniae strain (kind gift of Prof Gilbert Greub, Institute of Microbiology, Centre 
Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne) isolated from the 
CSF of a patient with acute community-acquired meningitis was used in all stimulation 
experiments. Bacteria were grown to log phase in brain-heart infusion medium, washed 
and resuspended in PBS at an OD620 of 1.0. Whole blood from five healthy Caucasian 
subjects was drawn into S-monovette-tubes (Sarstedt, Nümbrecht, Germany) containing 
16 U heparin/ml, diluted 5-fold in phenol red-free RPMI 1640 medium containing 2 mM L-
glutamine (Life Technologies, Grand Island, NY) (52). Blood was incubated at 37°C with S. 
pneumoniae (53). Penicillin and streptomycin (100 µg/ml) were added to the cultures one 
hour after stimulation. Cells were pelleted (500 × g for 5 min at room temperature) 24 
hours after stimulation and cell-free supernatants were used to measure MIF 
concentrations by ELISA (R&D Systems, Abingdon, UK). The lower limit of detection of the 
assay was 15.6 pg/ml. LDH was measured using the International Federation of Clinical 
Chemistry (IFCC) method to evaluate cell death. LDH concentration in samples (9.5-66 
units/l) remained in the normal range (i.e. <250 units/l). 
Patient cohort and controls. After identification by the Netherlands Reference Laboratory 
for Bacterial Meningitis (NRLBM, Academic Medical Center, Amsterdam) patients older 
than 16 years of age and with a positive CSF culture were enrolled between March 2006 
and June 2011 in a nationwide prospective cohort study (54). The study was approved by 
the medical ethics committee of the University of Amsterdam, the Netherlands. Treating 
physicians obtained informed written consent from either the patient or their legal 
representatives. Patients with culture-negative community-acquired or with hospital-
acquired bacterial meningitis were excluded. Controls consisted of co-dwelling non-related 
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patients proxies who shared environment and socio-economic milieu and provided a 
written informed consent (55). Demographic data including age, gender and ethnicity for 
both controls and patients were collected. A detailed medical history and extensive clinical 
and laboratory data were obtained from all patients. Outcome was evaluated at discharge 
according to the Glasgow Outcome Scale (GOS) with the following scoring system: score 
of 1 for death, score of 2 for persistent vegetative state, score of 3 for severe disability 
defined as a conscious patient who is dependent for daily activities, score of 4 for 
moderate disability defined as a patient with some deficits, capable of living independently 
but unable to return to work, score of 5 for a good recovery (56). A favorable outcome was 
defined as a score of 5 and an unfavorable outcome as a score of 1 to 4. A CSF leukocyte 
count below 1000 per mm3 was used as an indicator of disease’s severity (57). 
Blood collection and genotyping. Blood from patients and controls was collected in 
sodium EDTA. DNA extraction was performed by the Gentra Puregene isolation kit 
(Qiagen, Hilden, Germany) with quality control evaluation for DNA yield and purity. The -
794 CATT5-8 microsatellite (rs5844572) and the -173 G/C SNP (rs755622) were genotyped 
as reported previously (33). Given the frequencies of the -173 C minor allele and of the 
CATT7 allele in the Caucasian population, the study had 80% power to detect odds ratios 
(OR) of at least 1.5 for the susceptibility to infection, 1.9 for an unfavorable outcome and 
3.0 for mortality for these two alleles. These numbers were calculated using the Quanto 
1.2.3 software (http://biostats.usc.edu/software). 
CSF collection and MIF measurement. CSF was obtained from the first lumbar puncture, 
centrifuged and supernatant was aliquoted and stored at −80°C until analysis. Human MIF 
levels in the CSF were measured by the Luminex® technology using a Milliplex assay 
(Millipore, Billerica, MA, USA). The lower limit of detection of the assay was 12 pg/ml.  
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MIF promoter activity. A fragment ranging from -1073 to -129 bp of the MIF gene of 
either the -794 CATT5/-173 G, -794 CATT6/-173 G, -794 CATT6/-173 C, or -794 CATT7/-
173 C genotype was cloned in the pGL3-basic luciferase vector (Promega) (58). The 
human monocytic THP-1 (TIB-202, American Type Culture collection, Manassas, VA, 
USA) cell line was cultured in RPMI 1640 medium containing 2 mM L-glutamine, 50 μM 2-
mercaptoethanol and 10% heat-inactivated FCS (Sigma-Aldrich, St. Louis, MO). Forty 
thousand THP-1 cells in 96-well plates were transfected with 350 ng of the luciferase 
reporter vector together with 50 ng of the Renilla pRL-TK vector (Promega) (59). After 7 
hours, cells were incubated with S. pneumoniae (MOI 10). Penicillin and streptomycin (100 
μg/ml) were added to the cultures one hour after stimulation and incubation was continued 
for an additional 23 hours. Luciferase and Renilla luciferase activities were measured 
using the Dual-Luciferase Reporter Assay System (Promega). Results were expressed as 
the ratio of luciferase activity to Renilla luciferase activity. An empty vector served as a 
negative control (18). 
Mouse model of pneumococcal pneumonia and sepsis. Animal experimentations were 
approved by the Office Vétérinaire du Canton de Vaud (authorization number 877.8) and 
performed according to the institution and ARRIVE guidelines 
(http://www.nc3rs.org.uk/arrive-guidelines). Female BALB/cByJ mice (10 weeks-old; 
Charles River Laboratories, Saint Germain sur l'Arbresle, France) were housed under 
specific pathogen-free conditions. Mice (8 to 10 per treatment group) were injected 
intraperitoneally with two mg of rabbit anti-MIF or non-immune (control) IgG (obtained as 
described in (37)) administered two hours before an intranasal inoculation of 104 CFU of S. 
pneumoniae in anesthetized mice. Survival was monitored at least twice daily until the end 
of the experiment. In selected experiments, mice were sacrificed 48 hours after infection to 
obtain blood and lung tissue for the measurements of bacterial counts. 
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Statistical analyses. Graphs were generated with GraphPad Prism 6.0 (GraphPad 
Software, La Jolla, CA, USA). Data were analyzed using STATA version 11.1 (StataCorp 
LP, College Station, Texas, USA) and IBM SPSS Statistics 21.0 (IBM, Armonk, NY, USA). 
Genotype frequencies among patients and controls and Hardy-Weinberg equilibrium 
(HWE) were calculated using the chi square test. Tests for associations between MIF 
genotypes and susceptibility to and severity of pneumococcal meningitis were performed 
using logistic regression models. Stepwise multivariate selection was performed using a P 
value greater than 0.2 for removal of variables in the model. Sex, age and polymorphism 
carriage were forced into the model. Polymorphisms were analyzed using dominant 
(comparison of heterozygotes plus homozygotes versus wild-type carriers) and additive 
modes of inheritance (assessment of the effect of each additional copy of the minor allele). 
Strength of relationships between CSF levels and continuous variables was evaluated 
using Spearman’s correlation tests. Dichotomous variables were compared with the chi 
square test. Continuous variable for patient’s characteristics and disease parameters were 
assessed using Mann-Whitney U or Kruskall-Wallis tests. MIF promoter activity and 
concentrations of MIF released in whole blood after stimulation with S. pneumoniae were 
analyzed using one-way ANOVA for multiple comparisons. The log-rank test was used to 
compare the Kaplan-Meier survival curves. All tests were two-tailed and P values less than 
0.05 were considered to indicate statistical significance.  
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FIGURE LEGENDS 
 
Fig. 1. Carriage of -173 C or CATT7 high-expression MIF allelic variants is associated with 
death from pneumococcal meningitis. Proportions of survivors (white bars) and non-
survivors (black bars) for the -173 (G/G, G/C and C/C) and CATT7 (X/X, 7/X and 7/7) 
genotypes. Logistic regression analysis was performed using dominant and additive 
modes of inheritance (P=0.01 and 0.01 for -173 G/C and P=0.03 and 0.01 for CATT7, 
respectively).  
 
Fig. 2. S. pneumoniae induces MIF production in whole blood and polymorphic MIF alleles 
affect the transcriptional activity of the MIF promoter. (A) Whole blood from 5 healthy 
volunteers was stimulated for 24 hours with S. pneumoniae. MIF concentrations were 
measured by ELISA. Bottom, median and top lines of the box mark the 25th, 50th and 75th 
percentiles. Vertical lines with whiskers show the range of values. P=0.005 (2 x 106), 
P=0.001 (2 x 107) and P<10-8 (2 x 108) when compared to control. (B) THP-1 monocytes 
were transiently transfected with CATT5/-173 G, CATT6/-173 G, CATT6/-173 C and 
CATT7/-173 C MIF promoter pGL3 and Renilla luciferase vectors. Cells were stimulated for 
24 hours with (solid bars) or without (open bars) S. pneumoniae (MOI 10). Data are means 
+ SD of 3 independent experiments performed in triplicates. P=0.05 (CATT6/-173 G), 
P=0.04 (CATT6/-173 C) and P=0.007 (CATT7/-173 C) for S. pneumoniae vs. control. After 
S. pneumoniae stimulation, P=0.03 (CATT6/-173 C) and P=0.003 (CATT7/-173 C) when 
compared to CATT5/-173 G.  
 
Fig. 3. Anti-MIF antibody protects against lethal pneumococcal pneumonia and sepsis. 
Mice were treated with anti-MIF or non-immune (control) IgG (2 mg injected 
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intraperitoneally) given two hours prior to an intranasal inoculation of 104 CFU of S. 
pneumoniae. (A) Box plots of bacterial counts in the lung 48 hours after infection. Data are 
from five independent experiments with a total of 34 mice per treatment group. Bottom, 
median and top lines of the box mark the 25th, 50th and 75th percentiles. Vertical lines with 
whiskers show the range of values. P=0.008 (Mann-Whitney U test). (B) Kaplan-Meier 
survival plot. Data points are from three independent experiments with a total of 28 mice 
per treatment group. P=0.04 (log-rank test). 
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Table 1. Characteristics of controls and patients with pneumococcal meningitis. 
Characteristics  Controls 
n=343 
Patients 
n=461 
Age (years) 59.4 ± 18.1 60.1 ± 20.8 
Female gender  146 (49.2) 220 (47.0) 
Caucasian ethnicity 329 (96.0) 434 (94.2) 
 
Causasian patients with 
DNA and outcome 
(n=405) 
Predisposing factors (n=405)  
 Otitis/sinusitis 191 (47.3) 
 Immunocompromised status 100 (24.7) 
Body temperature in °C (n=401) 39.0 ± 1.5 
Glasgow coma scale < 8 (indicating coma) (n=402) 53 (13.2) 
Bacteremia (n=357) 287 (80.4) 
Neurologic complications (n=404) 257 (79.6) 
Systemic complications (n=396) 151 (38.1) 
Complications (n=405)  
 Shock 25 (6.2) 
 Respiratory failure 93 (23.0) 
 ICU admission 177 (43.7) 
 Mechanical ventilation 140 (34.6) 
Outcome  
 Glasgow Outcome Scale (n=405)  
  1: Death 30 (7.5) 
  2: Persistent vegetative state 1 (0.2) 
  3: Severe disability 18 (4.4) 
  4: Moderate disability 84 (20.7) 
  5: Good recovery 272 (67.2) 
 Hearing loss at discharge (n=368) 41 (11.1) 
Data are mean ± IQR or number (percent). ICU: intensive care unit. 
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Table 2. Association between MIF gene polymorphisms and patient’s outcome.  
 Unfavorable outcome 
(GOS ≤ 4; n=133) 
Respiratory failure 
(n=93) 
Death 
(n=30) 
Polymorphisms OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value 
GC/CC vs GG 1.9 (1.24-2.92) 0.003 1.71 (1.06-2.74) 0.03 2.6 (1.01-3.78) 0.01 
55/5X vs XX 0.88 (0.58-1.33) 0.54 0.87 (0.54-1.39) 0.56 0.66 (0.31-1.43) 0.30 
66/6X vs XX 0.98 (0.57-1.68) 0.93 1.05 (0.57-1.93) 0.89 1.48 (0.50-4.38) 0.48 
77/7X vs XX 1.89 (1.21-2.96) 0.005 1.41 (0.98-2.63) 0.06 2.27 (1.07-4.83) 0.03 
 
Logistic regression analysis using a dominant model of inheritance. 
GOS: Glasgow outcome scale. 
28 
 
Table 3. Multivariate logistic regression analysis for death and unfavorable 
outcome. 
Prediction OR (95% CI) P value 
Death (n=30/398)   
 Shock 26.06 (5.36-48.09) 0.02 
 Carriage of CATT7 allele 5.12 (1.11-23.67) 0.04 
 Immunocompromised state 2.85 (1.16-6.98) 0.09 
 Male gender 2.48 (0.99-6.17) 0.05 
 Age (per year increase) 1.04 (1.01-1.08) 0.02 
Unfavorable outcome (n=133/405)   
 Systemic complications on admission 15.8 (1.80-137.97) 0.01 
 Otitis or sinusitis 3.79 (2.21-6.49) < 0.001 
 Carriage of CATT7 allele 2.61 (0.91-7.50) 0.07 
 Male gender 1.67 (0.96-2.91) 0.07 
 Age (per year increase) 1.01 (0.99-1.03) 0.18 
 GCS > 12 0.54 (0.29-1.01) 0.06 
 
GCS: Glasgow coma score 
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Supplementary Table 1.  MIF allelic frequencies and genotypes in patients with pneumococcal meningitis and in controls. 
MIF gene polymorphism Allele Patients 
 (%) 
HWE P 
value 
Controls 
 (%) 
HWE P 
value 
Genotype Patients 
 (%) 
Controls 
(%) 
P value 
-173 G/C (rs755622) G 697 (80.3)  542 (82.4)  GG 283 (65.2) 223 (67.8)  
 C 171 (19.7) 0.3 116 (17.6) 0.9 GC 131 (30.2) 96 (29.2)  
      CC 20 (4.6) 10 (3.0) 0.5 
CATT5-8 (rs5844572) CATT 5 213 (24.6)  164 (25.0)  CATT 5-5 26 (6.0) 24 (7.3)  
 CATT 6 513 (59.2)  398 (60.7)  CATT 5-6 129 (29.8) 99 (30.2)  
 CATT 7 139 (16.1)  94 (14.3)  CATT 6-6 153 (35.3) 117 (35.7)  
 CATT 8 1 (0.1) 0.9 0 (0) 0.7 CATT 6-7 77 (17.8) 65 (19.8)  
      CATT 5-7 32 (7.4) 17 (5.2)  
      CATT 7-7 15 (3.5) 6 (1.8)  
      CATT 5-8 0 (0) 0 (0)  
      CATT 6-8 1 (0.2) 0 (0) 0.6 
CATT/-173 haplotype      5G 212 (24.5) 163 (24.9)  
      6G 479 (55.3) 375 (57.3)  
      6C 36 (4.2) 22 (3.4)  
      7C 132 (15.2) 92 (14.1)  
      8C 1 (0.1) 0 (0)  
      5C 1 (0.1) 0 (0)  
      7G 5 (0.6) 2 (0.3) 0.8 
HWE: Hardy-Weinberg equilibrium. Calculation of allele frequencies based on 2xN patients or controls. Genotypes were obtained from 
434 (-173 G/C) or 433 (CATT5-8) patients and 329 (-173 G/C) or 328 (CATT5-8) controls. 
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